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The effect of desferrioxamine on concentration and distribution of
aluminum in bone. Aluminum (Al) loaded rats were injected chronically
with either desferrioxamine (DFO) or saline. Six rats of each treatment
group were sacrificed before and after one, three, and nine months of
treatment for determination of tissue and serum Al, and for histological
localization of bone Al. Urinary Al was measured during one week
before sacrifice. Al loading caused significant elevations of bone (136,2
22.0 jig/g) and liver (114.4 41.9 sg/g) aluminum. Serum Al in
DFO-treated animals was not different from their controls (216.4 80.5
and 226.9 42.9 gig/liter after one month; 151.0 20.8 and 138.0
63.9 g/liter after three months; 72.1 40.7 and 61.6 14.2 rg/1iter
after nine months in control and DFO-treated animals respectively).
Urinary Al excretion in the DFO-treated group was increased at all
times as compared to the control rats. A decrease of muscle Al occurred
after one month of DFO treatment, hut no significant differences of liver
and bone Al could be shown between DFO-treated rats and their
controls. Al decreased to a comparable degree in all tissues of both
DFO and control rats after nine months of treatment. Histomorpho-
metric examination of the bones showed that after one and three
months of treatment, significantly less Al was localized at the calcifi-
cation front of DFO-treated rats compared to their controls (75.6
6.9% and 53.4 20.9% after one month; 52.3 10.2% and 34.8
10.6% after three months in control and DFO rats respectively). These
results suggest that in rats, DFO: a) promotes an increase of urinary Al
excretion; b) does not influence total Al bone content; and c) decreases
the Al localized at the calcification front. These data may apply only to
animals with intact renal function.
Aluminum (Al) accumulation causes important medical prob-
lems in patients with chronic renal failure, since it provokes a
debilitating bone and brain disorder, often with a fatal outcome
[1, 21. The toxic nature of Al has been shown by epidemiologic
reports [3—7], by the occurence of increased Al concentrations
in the affected tissues [1, 8, 9], and by the induction of bone
disease in animals by Al administration [10—13]. Desfer-
rioxamine (DFO), a chelator that effectively binds Al, is capable
of increasing the Al excretion [14, 15], and some reports have
underlined its beneficial effect in Al related diseases [15—191.
The improvement in the clinical condition of the patients has
been attributed to the quantitative mobilization of tissue Al
after DFO treatment [17—191.
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The present study was undertaken to study the effect of DFO
on Al removal of bone and other tissues in Al-loaded rats.
Methods
Aluminum loading. Male wistar rats weighing 200 to 220 g
were given 20 intraperitoneal injections of a 1 mliter aluminum
chloride solution containing 2 mg Al over a six week period
(four times a week during the first four weeks, and two times a
week during the last two weeks). The cumulative dose of Al
administered to each rat was 40 mg. During the entire experi-
ment, the rats were fed ad libitum their ordinary rat chow and
they had free access to drinking water. Rat chow A04 contains
5.7 0.5 g/kg calcium and 5.7 0.6 g/kg phosphorus according
to the manufacturer (UAR, Epinay France).
DFO treatment. Two weeks after stopping parenteral Al
administration 36 animals were randomly divided in two
groups. The control group received I mliter of physiologic
saline, the other group desferrioxamine, 50 mg dissolved in 1
muter saline. Saline or desferrioxamine were administered
intraperitoneally thrice a week up to the moment of sacrifice.
Urine collection. Urine was obtained by housing six rats of
each group in individual metabolic cages. Five consecutive 24
hr samples were collected for the determination of urinary
volume, creatinine, and Al concentrations. Collections were
performed after the Al loading period and after one, three, and
nine months of DFO treatment. Urinary Al excretion is ex-
pressed as mg Aug creatinine and as j.rg Al/day. The urinary
concentrations were calculated as the mean of the 24 hr samples
in each rat. The mean of these figures for the six rats is
reported.
Evalua lion of Al contamination due to the presence of
unsaturated DFO in the urine. Twelve normal rats were housed
in metabolic cages for three days under the same circumstances
as in the experiment. To each of the recipients used for the
collection of the urine of six rats, 1 muter saline containing 50
mg DFO was added. Three consecutive 24 hr samples were
collected.
Collection of blood and tissues. A first collection of blood and
tissues was performed in six rats two weeks after stopping the
Al administration. In another series of six rats, killed after the
Al loading, the Al content of the carcasses was determined.
After blood sampling, the organs specified below were re-
moved. The gastrointestinal tract was discarded to avoid con-
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tamination from the Al present in the feces; afterwards the rats
were skinned and homogenized using a mincer. These
homogenates were stored at —20°C for later Al analysis. The
other animals were killed after one, three, and nine months of
treatment with either DFO or saline. In these animals, there
was always a lag of time of at least two days between the last
injection of the DFO solution or saline and sacrifice, Blood was
obtained by cardiac puncture after thoracotomy, and brain,
muscle, liver, and both femurs were taken at that moment.
Histological quantitation of Al in bone. Quantitative bone
histology for measurement of Al was performed on midsagittal
sections of the femur head. Bone tissue was fixed in 5%
buffered formalin, dehydrated and embedded in Resin Adam
without prior decalcification. Six micrometer thick sections
were cut using a Jung K microtome. These sections were
stained with the von Kossa and the aluminon (aurine
tricarboxylic acid) techniques [20]. In the procedure, Al ap-
peared to stain as red bands at the outer edges of the mineral-
ized bone and in the cement lines. The percentage of trabecular
surface and of cement lines covered by Al was estimated by a
line—intersect technique using a Zeiss eyepiece graticule. In
each bone, 36 fields were examined and the means of these
measurements were calculated. The means of these figures for
the six rats are reported.
Chemical analyses. Serum and urine Al were determined by
means of flameless atomic absorption as previously described
[21]. The coefficient of variation of Al determinations in serum
and urine estimated by separate analysis of 6 aliquots of the
same sample was found to be 4.2%. For the analysis of tissues
and carcases, the EDTA extraction method of LeGendre and
Alfrey was used [22, 23]. The hetween run precision of this
method, estimated by separate analysis of 5 aliquots of the same
bone sample, was 4.4%. Analysis of minced carcasses of
control rats not receiving Al showed concentrations below 0.5
/.Lg/g dry wt, excluding Al contamination by the mincing proce-
dure.
Creatinine was analyzed with the Jaffe method.
Statistical analysis. Statistical comparisons were performed
by one—tailed Student's t-tests. If the variances of the groups to
be compared differed significantly, the Cochrans test was
performed. For comparison of the histological results, the
Mann—Whitney test was used. All statistical analyses were
performed by the BALANCE program [24]. All results are
expressed as mean SD.
Results
Figure 1 shows that after the loading period with Al, in-
creased amounts of Al were found in bone, liver, and muscle.
Brain concentrations, however, were not significantly different
from normal values. The total carcass Al content was 106.3
9.7 zg/g dry wt, or 7.4 0.4 mg/rat when taking into account
the Al content of the tissue samples analyzed separately.
Table 1 summarizes the results of tissue Al concentrations in
DFO treated and control rats. After one month of treatment,
total bone Al still tended to increase in both DFO-treated and
control rats. When compared with the initial month 0 value,
however, the changes were not statistically significant. After
three months of treatment the concentration again reached the
initial value. A significant decrease of bone Al was only
observed after nine months of treatment. There was no differ-
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Fig. 1. Tissue Alof rats intraperitoneally loaded wi/li 40 mg qfAl (open
bars), compared to non loaded animals (closed bars). The results are
expressed as mean SD.
Bone
Control DFO
Liver
Control DFO
Muse
Control
le
DFO
Month 0 136.2
22.1
— 114.4
41.9
— 8.9
4.1
—
Month 1 156.5
19.8
158.9
15.3
94.7
28.6
126.4
35.1
7.2
1.1
4.2*
0.5
Month 3 127.3
17.3
130.4
23.2
67.0
12.5
63.0
25.6
6.2
0.8
5.3
1.2
Month 9 77.3
18.8
79.2
10.2
25.5
16.2
17.4
3.1
4.1
1.1
3.9
1.0
Normal 1.3
0.6
1.7
0.8
1.6
0.8
ence in the Al content of bone between DFO- and saline-treated
animals.
In muscle and liver the Al content seemed to decrease
gradually. Significantly lower concentrations were noticed in
both groups for liver and muscle after three and nine months of
treatment, respectively.
Comparison of the DFO-treated group with the control group
revealed that the only difference between them was observed in
muscle after one month of treatment. In none of the other
tissues could a difference in Al concentration be found.
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Table 1. Tissue Al content (/ig/g dry wt) in control and DFO-treated
animals before and after 1, 3 and 9 months of treatment
Symbol is: * P < 0.05 (DFO vs. control). Results are mean SD.
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Fig. 2. Histomorphometric determination of Al covering the bone
trabecula of Al loaded rats, treated with DFO (closed bars) or saline
(open bars). The results are expressed as % bone surface covered by Al
positive staining. * P < 0.05, compared to controls.
Histological examination of the bone showed no evidence of
osteomalacia. As shown in Figure 2, histomorphometric mea-
surement reveals that at time 0, 55.5 9.5% of bone trabecula
were surrounded by Al positive staining. In the rats given saline
for one month, this amount increased significantly to 75.6
6.9% while it remained unchanged in the DFO-treated group.
After three months of DFO treatment, a significant decrease
(34.8 10.6%) compared to time 0 was observed. These
measurements were also significantly different from those ob-
served in animals treated for three months with saline (52.3
10.2%). Photomicrographs (Fig. 3) show that up to one month
after stopping Al administration, virtually all Al was localized at
the calcification front. After three months of treatment with
either DFO or saline, Al was also found within the cement lines,
but upon quantitation, the number of Al-positive cement lines
was identical in both groups (18 3% for both the treated and
untreated animals).
Serum Al concentrations, measured after stopping the Al
loading and after one, three and nine months of treatment, are
given in Table 2. It was obvious that the loading of the rats with
Al resulted in markedly increased serum Al concentrations
(normal value: less than 3 rg/liter). After three months of
treatment serum Al decreased significantly in both groups, A
further significant decrease was observed after a nine month
treatment period. However, at no time during the experiment
could a significant difference be shown between DFO-treated
and control rats.
Urinary Al excretion (Table 3) was markedly increased after
the loading period with Al. Urinary excretion of Al in normal
rats was found to be 0.39 0.09 sg/day [251. During treatment,
a significant decrease of the Al urinary excretion was noticed in
both groups. At each collection time during treatment, the
urinary excretion of Al in DFO-treated rats exceeded the values
Fig. 3. Photomicrographs of bone of Al loaded rats. The dark lines
represent the Al positive staining. A. before treatment. All Al is
localized at the calcification front. B. three months control. C. three
months DFO treatment. Al positive staining is observed both at the
calcification front (a) and within the cement lines (b).
observed in controls. The addition of unsaturated DFO to the
urine of normal rats increased the Al content to 0.82 0.36
gIday. The amount of Al present in the DFO was found to be
0.22 Lg/50 mg. A maximal net increase, due to contamination,
of about 0.20 1Lg/day can therefore be attributed to the presence
of unsaturated DFO in the urine.
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Table 2. Serum Al concentrations (jig/liter) at the start and after 1, 3
and 9 months of treatment with either DFO or saline
Months 0 1 3 9
Control 480.2 216.4
113.9 80.5
151.0
20.8
72.1
40.7
DFO treatment 226.9
42.9
138.0
63.9
61.6
14.2
Normal value Less than 3 jig/liter
Results are mean SD.
Time 0 I Month 3 Months 9 Months
Control
jig/day 119.9
47.2
34.7
2.4
13.0
1.6
7.5
2.6
mg/g creatinine 10.6
4.35
2.51
0.36
0.98
0.17
0.57
0.25
DFO treatment
jig/day 459**
8.1
26.0**
9.3
15.3**
4.1
mg/g creatinine 343*
0.92
2.02**
0.35
1.08'
0.30
Normal value
jig/day 0.39
0.09
jig/g creatinine 43.4
11.7
Symbols are: * P < 0.05; ** P < 0.01 (DFO vs. control). Results are
mean SD.
The mean serum creatinine after Al loading (time 0) was 0.63
0.10 mg/dliter, illustrating normal renal function. Body wt
was not different in control and DFO rats as shown in Figure 4.
Discussion
In this experiment, Al loaded rats were used since previous
studies have shown that these animals provide a good model for
the study of the Al intoxication syndrome [10—12]. The present
study confirms that Al loading results in a marked increase of Al
in serum, urine and in some tissue; both bone and liver have a
high Al content, while muscle Al increases moderately. The
mean brain Al content in this study was not different from
non-Al loaded animals. These data on tissue accumulation of Al
confirm previous animal experiments [25]. The bone Al concen-
trations observed here are also comparable with those found in
patients with the Al intoxication syndrome [1, 9, 10, 28, 291.
An interesting part of this experiment is the evolution of
tissue Al in both the DFO-treated and the control group. After
stopping the Al loading, total bone Al concentration tended to
increase although the changes were not statistically significant;
the value then decreased significantly from the initial value to
the measurement at nine months. This decrease of total hone Al
is observed in both groups, indicating that even without specific
treatment Al can be mobilized. Since a decrease is observed in
all tissues studied, it is most likely that body burden can
decrease spontaneously by slow but continuous Al excretion
once the Al administration is stopped. In our study, spontane-
ous decreases in tissue Al were observed after three months in
liver, but only after nine months had the content in both bone
and muscle significantly lowered. This suggests that in animals
with normal renal function, the removal of tissue Al occurs very
slowly. Slow spontaneous removal of Al has also been noted in
patients with parenteral, nutrition—associated Al intoxication,
as well as in patients with renal failure on dialysis [30, 31]. In a
patient with aluminum—related bone disease due to aluminum
present in total parenteral nutrition solutions, repeated bone
biopsies showed a decrease of stainable Al after 42 months and
a disappearance after another 12 months [30]. In dialysis
patients, spontaneous decrease of bone Al content and im-
provement of symptomatic bone disease required more than
four years [31].
The effect of DFO on the Al content of different tissues is
unexpected. As shown in Table 1, the only difference between
the DFO and the control group was a significant fall of muscle
Al content within the first month of DFO treatment. The
meaning of this lowered muscle Al is not clear since further
significant decreases were only noticed after nine months of
treatment. Bone and liver did not differ from controls at any
time of examination.
During the treatment period, we could not observe a differ-
ence between the serum Al concentration of the DFO and the
control group. At first sight, this finding is at variance with
studies in humans showing a consistent increase of serum Al
after DFO administration [14, 15], and a study in rabbits that
showed an increase of serum At during hours following DFO
administration [32]. In our rats blood was obtained at sacrifice
two days after the last DFO administration. We could, there-
fore, have missed the DFO-induced increase of serum Al,
because serum Al had already returned to its baseline concen-
600
Table 3. Urinary Al excretion in control and DFO-treated rats at the
start and after I, 3 and 9 months of treatment with either saline or
DFO
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Fig. 4. Evolution of hody weight in cootrol and DFO-treoted rots.
72 Verbee/en ci al
tration. It seems also, from recent work in humans, that the
increase of serum Al after DFO administration is less pro-
nounced after some weeks of treatment [19]. The species
difference, the absence of renal failure, and the fact that the first
serum analyses were performed only after one month of treat-
ment could help to explain why no increase of serum Al in the
DFO-treated group could be demonstrated.
The DFO-treated rats, however, systematically excreted
more Al, since compared to the controls their urinary Al
excretion was larger. The average excess urinary Al in the
treated group was about 10 g/day, which approximately re-
suits in the removal of an extra 2.7 mg over the nine month
period of treatment. This amount represents about one—third of
the measured body burden. The origin of this increased urinary
Al excretion under DFO cannot be evaluated from our data
since no difference could he evidenced between tissue concen-
tration in treated and non-treated animals. The possibility of a
contamination by unsaturated DFO excreted in the urine that
takes up Al from the environment (metabolic cages, spilled
food, dust, etc.) was investigated. A contamination of about
0.20 pg/day can be expected if unsaturated DFO is present in
the urine. This small difference, however, cannot explain the
average excess urinary Al observed in the DFO-treated group
which was found to be 10 pg/day. A possible explanation is that
DFO picks up Al from organs and sites not included in this
study, such as the gastrointestinal tract and the peritoneal
cavity. Another possibility could be that DFO increases gut
absorption rather than increasing its excretion. A more detailed
investigation of the effect of DFO on Al kinetics in the gastro-
intestinal tract could help to elucidate this point, It is notewor-
thy that also in Al-loaded rabbits, the Al content of different
tissues does not change significantly after subchronic DFO
administration [33]. In humans treated with DFO for Al intox-
ication, most authors except Brown et al [161 describe a fall of
bone Al content [17—20]. It is, therefore, possible that the
mobilization of Al by DFO is different in uremics on dialysis
and animals with normal renal function. Since no controlled
study of the effect of DFO on tissue Al in humans on dialysis is
available, the possibility of a spontaneous decrease of tissue Al
in those patients cannot be excluded.
In the present study, histomorphometry reveals that in con-
trols the percentage of trabecula covered with Al increased
from 55.5 9.5% to 75.6 6.9% after one month, and returned
three months after stopping Al administration to 52.3 10.2%,
which was not different from the measurement at the start. Our
data also show that, despite the fact that total bone Al is not
different in both groups, DFO-treated rats had significantly less
Al localized at the calcification front. The amount of stainable
Al in the cement lines was not different in control and DFO-
treated rats. Possible explanations for the selective decrease of
Al at the calcification front are that in the DFO-treated rats, the
DFO bound plasma Al prevents the deposition of Al at the
calcification front, or that DFO is able to remove the Al from
this site. Since there was no evidence of osteomalacia in our
rats, no effect of DFO on bone histology could he observed.
The difference between chemical and histological Al determi-
nations has also been observed by others 19, 29, 341.
Cournot—Witmer et at showed that in patients with Al bone
disease, Al could be localized at the calcification front, whereas
in patients exposed to Al, but without Al bone disease, the Al
was either localized in the cement lines or was not detectable,
even in the presence of increased bone Al concentration [29].
Also, using x-ray microanalysis, it has been shown that the high
concentration of Al at the calcification front is at the limit of
detection of the technique, and thus, that failure to detect Al at
other sites does not imply its absence [35]. The effect of DFO on
this localization however has not been described.
In conclusion, our data show that in Al-loaded rats, DFO
treatment results in an increased urinary Al excretion and a
decrease of Al localized at the calcification front of bone. It is
possible that these findings in animals with normal renal excre-
tory mechanism for Al might not apply to the situation in
patients on regular dialysis therapy, where there is little or no
means to rid the body of aluminum.
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